MicroRNAs (miRs) can promote or inhibit tumor growth and are therefore being developed as targets for cancer therapies. They are diverse not only in the messenger RNAs (mRNA) they target, but in their production; the same hairpin RNA structure can generate mature products from each strand, termed 5p and 3p, that can bind different mRNAs. We analyzed the expression, functions, and mechanisms of miR-28-5p and miR-28-3p in colorectal cancer (CRC) cells.
C olorectal (CRC) cancer is the third most commonly diagnosed cancer in men and the second in women. 1 In the United States, it is the third leading cause of death by cancer, with 51,371 estimated deaths and 142,570 estimated newly diagnosed cases in 2010. 2 Therefore, new therapeutic approaches and prognostic markers are needed. In 2002, new players in cancer biology were identified: microRNAs (miRNAs). 3 These are a large family of small noncoding RNAs with approximately 20-nt length that regulate gene expression post-transcriptionally by inhibition of translation or messenger RNA (mRNA) degradation. 4 miRNAs targeting occurs by binding to 3=-untranslated regions, coding sequences, or 5=-untranslated regions of target mRNA that can be involved in diverse biological processes, such as proliferation, apoptosis, inflammation, differentiation, and metastasis. 4 miRNAs can function as either oncogenes or tumor suppressor genes, depending on the type of tumor or the cellular context. 5 In CRC, miRNAs have been involved in tumor susceptibility (as polymorphisms in miRNA-binding sites have been associated with CRC risk) and in diagnosis (as miRNAs can be detected in feces or blood and used as biomarkers). 6 In addition, miRNA expression is dysregulated in CRC, as well as in other cancer types, and miRNAs have emerged as potential new therapeutic targets. 6, 7 Therefore, understanding the role of miRNAs in CRC is crucial for the development of new therapies.
In the miRNA biogenesis pathway, long primary transcripts transcribed from the genome are processed by the cellular RNase enzyme III Drosha into a structure of 60 to 110 nt called precursor miRNA (pre-miRNA), which is then exported to the cytoplasm by an Exportin 5-dependent mechanism. 4 The pre-miRNA is cleaved by the RNase III enzyme Dicer-1 producing a short, imperfect, doublestranded miRNA duplex, which is unwound by a helicase, creating a mature miRNA. 4 In some cases, 2 mature miRNAs can be excised from the same stem-loop pre-miRNA. 8 These 5p and 3p miRNAs, although generated from a single primary transcript, have different sequences and therefore tar -1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 AQ: 7 get different mRNAs. In humans, 2 different mature miRNA sequences are excised from opposite arms of the stem-loop pre-miR-28 and generate 2 different miRNAs-hsa-miR-28-5p and hsa-miR-28-3p. Despite nearly a decade of studies on miRNA roles in cancer, 3 the comparative roles of strandspecific mature miRNAs that originated from the same stem-loop precursor (5p and 3p ) have not yet been fully studied.
To our knowledge, the roles miR-28-5p and miR-28-3p play in CRC has never been described. Therefore, the purpose of our study was to analyze miR-28-5p and miR-28-3p expression and to use in vitro and in vivo approaches to understand, for the first time, the functions and mechanisms of these 2 miRNAs in CRC.
Materials and Methods

Colorectal Samples
Eighty-five CRC samples and 26 normal colorectal tissue samples (of which 24 were paired) were collected between 2003 and 2008 at the University Hospital of Ferrara in Ferrara, Italy (first sample set). Forty-two tumors were classified as microsatellite stable (MSS), and 43 tumors were classified as microsatellite unstable (MSI) (Supplementary Methods). For a confirmation set of samples, we obtained 23 paired samples of tumor and adjacent colorectal tissue that were collected between 2002 and 2005 at the Istituto per lo Studio e la Cura dei Tumori della Romagna in Meldola, Italy (second sample set). Tumors were classified according to the World Health Organization pathologic classification system. All patients provided informed consent, and collection of the samples was approved by the institutional review board at each institution. Patients did not receive any therapy before surgery. Upon resection, fresh surgical specimens were immediately snap-frozen in liquid nitrogen and stored at Ϫ80°C. Total RNA from tissue samples was isolated using Trizol reagent (Invitrogen, Carlsbad, CA), according to manufacturer's instructions (Supplementary Methods).
Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction
RNA purity was assessed by measuring absorbance at 260, 280, and 230 nm. Mean 260/280 ratio was 1.97 Ϯ 0.05, with a range between 1.86 and 2.05, and mean 260/230 ratio was 2.17 Ϯ 0.11, with a range between 2.00 and 2.31. In addition, as recommended by the Minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines, 9,10 we analyzed RNA integrity by gel electrophoresis and clearly defined 28S and 18S ribosomal RNA bands were visualized. Samples with low quality that did not meet these criteria were excluded. We quantified miR-28-5p and miR-28-3p expression with real-time quantitative polymerase chain reaction TaqMan miRNA assays (Applied Biosystems, Foster City, CA), namely assay 000411 for miR-28-5p, assay 002446 for miR-28-3p, and assay 001973 for U6 snRNA (Supplementary Methods). The efficiency of the Taqman assays used in this study was determined (Supplementary  Figure 1 and Supplementary Table 1 ). Relative expression levels were calculated using the ⌬⌬C t 11 and the Pfaffl method. 12
In Vitro Cell Proliferation Assays
HCT116 and RKO cells transfected with scrambled control (SCR), miR-28-5p, or miR-28-3p were seeded onto a 12-well plate at 1 ϫ 10 5 cells/well in triplicate. Cells were harvested and counted at 0, 24, 48, 72, and 96 hours after transfection using the Vi-CELL cell viability analyzer (Beckman Coulter, Brea, CA). In order to further confirm our results, a 3-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed (Supplementary Methods). The experiment was repeated twice independently.
In Vitro Cell Migration and Invasion Assays
To determine the effect of miR-28-5p and miR-28-3p on cell migration, we used 6.5-mm diameter Transwell chambers with 8-m pore size polycarbonate membranes (Corning Incorporated, Lowell, MA). To determine the effect of these miRNAs on cell invasion, we used BioCoat growth-factor reduced Matrigel invasion chambers (BD Biosciences, Bedford, MA). Cells transfected with SCR, miR-28-5p, or miR-28-3p were resuspended in serum-free medium and plated on the top of the Transwell chambers. Fetal bovine serum was used as a chemoattractant on both assays. Each assay was performed in triplicate and in 2 independent experiments. Additional details are described in Supplementary Methods.
In Vivo Studies of Tumorigenesis and Metastatic Potential
For the in vivo tumorigenesis assay, 1.5 ϫ 10 6 HCT116-pBABE-miR28 or HCT116-pBABE-empty cells were subcutaneously injected into the flanks of NOD-SCID-IL2RϪdeficient mice (n ϭ 9; stock #005557; The Jackson Laboratory, Bar Harbor, ME). Tumor size was measured every 2 days. Animals were sacrificed 21 days after injection, and final tumor volume was determined. Tumor size was determined by digital caliper measurements (length and width in mm), and tumor volume (mm 3 ) was estimated using the following formula: tumor volume ϭ ½ (length ϫ width 2 ).
For the in vivo tumor-metastasis assay, 4 ϫ 10 6 HCT116-pBABE-miR28 and HCT116-pBABE-empty cells were injected into the tail vein of NOD-SCID-IL2R-deficient mice (n ϭ 11/ group). Thirty-five days after injection the mice were sacrificed. All of the organs were examined at necropsy. Tumors were sectioned, stained with H&E, and antiϪgreen fluorescent protein antibody (Ab13970; Abcam, Cambridge, MA), and examined histologically.
All animal care and handling was approved by The University of Texas MD Anderson Institutional Animal Care and Use Committee.
Statistical Analysis
Shapiro-Wilk test was used to verify the clinical samples' distribution. Differences were analyzed using the nonparametric test Mann-Whitney-Wilcoxon. To compare the paired groups, paired t test was used. For in vitro and in vivo studies, the differences between groups were analyzed using Student t test (2-tailed), assuming unequal variance. Discrete variables were compared with Fisher exact test. Graphics represent the mean Ϯ standard deviation, unless otherwise stated. Statistical analysis was performed in R (version 2.11.0). Statistical significance was considered if P Ͻ .05.
Additional methods, including cell culture, STR DNA fingerprinting, and miRNA mimics transfection, apoptosis quantification, caspase activity, cell cycle analysis by flow cytometry, establishment of miR-28 -expressing cell line, miRNA target prediction, Western blot, and luciferase reporter assays, are available in Supplementary Methods.
Results
miR-28-5p and miR-28-3p Are Down-regulated in CRC
Expression levels of miR-28-5p and miR-28-3p were analyzed by quantitative real-time polymerase chain reaction (PCR) in 85 human CRC specimens and 26 normal human colorectal specimens. In order to ensure that the reference gene snRNA U6 does not change between normal and tumor samples, we calculated the mean C t values as 2 ϪCt . Levels of U6 did not differ between normal and tumor tissue, 2 ϪCtTumor /2 ϪCtNormal ϭ 0.94 (P ϭ .41) (Supplementary Figure 2) . Both miRNA-28-5p and miR-28-3p were significantly down-regulated in CRC samples (miR-28-5p, P Ͻ .005; miR-28-3p, P Ͻ .005) ( Figure  1A ). Both MSS (n ϭ 42) and MSI (n ϭ 43) tumors showed down-regulation of miR-28 expression compared with the normal colon tissue (miR-28-5p normal vs MSS, P Ͻ .005 and normal vs MSI, P Ͻ .005; miR-28-3p normal vs MSS, P Ͻ .005 and normal vs MSI, P Ͻ .005); however, no significant differences between MSS and MSI tumors were found (miR-28-5p MSS vs MSI, P ϭ .418; miR-28-3p MSS vs MSI, P ϭ .996) ( Figure 1B) . We also analyzed the expression of these miRNAs in the subset of 24 pairs of normal and tumor tissue samples from the same patients, and in agreement with these data, we found significant down-regulation of miR-28-5p and miR-28-3p in CRC Figure 3) . In order to confirm these results, we used a second independent set of CRC samples. In 23 paired samples of tumors and adjacent normal tissue, we also found that both miRNAs were downregulated (miR-28-5p, P Ͻ .001; miR-28-3p, P Ͻ .001) ( Figure 1C ). Values of expression are presented in Supplementary Tables 2 and 3 .
miR-28-5p, but Not miR-28-3p, Significantly Suppresses Proliferation and Induces Apoptosis and G1 Arrest in CRC Cells
To elucidate the roles of miR-28-5p and miR-28-3p in CRC tumorigenesis, HCT116 and RKO CRC cell lines (endogenous miR-28 expression levels of colon cell lines are shown in Supplementary Figure 4) were transfected with SCR, pre-miR-28-5p, or pre-miR-28-3p. Expression of miRNAs was confirmed by quantitative real-time PCR (Supplementary Figure 5) . In both cell lines, we found that cells overexpressing miR-28-5p grew significantly less (P Ͻ .005) than did cells transfected with control or miR-28-3p (Figure 2A and B) . This result was also confirmed in the HCT116 and RKO cell lines using the 3-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Supplementary Figure 6A and B) . In contrast, in both cell lines overexpressing miR-28-3p, there were no statistically significant differences at any time (HCT116, P ϭ .25; RKO, P ϭ .81) compared with cells transfected with control (Figure 2A and B) . Therefore, the in vitro results suggest that miR-28-5p, but not miR-28-3p, has a biological effect on proliferation.
We then explored the possibility that the effect of miR-28-5p on proliferation could be due to an increase in 174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231   C  O  L  O  R   174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231 F2 apoptosis or to defects in the cell cycle. To test whether miR-28-5p had an effect on apoptosis, we measured poly-(adenosine diphosphate-ribose) polymerase 1 (PARP1) protein, which is specifically cleaved by caspases and promotes apoptosis. PARP1 cleavage forms are one of the most reliable apoptotic markers. 13, 14 Cells transfected with pre-miR-28-5p expressed 2.2 and 1.8 times more cleaved-PARP1 form (relative to total-PARP1 form) than did cells transfected with control in the HCT116 and RKO cell lines, respectively ( Figure 2C ). In agreement with the results of the proliferation assays, cells transfected with miR-28-3p presented a PARP1 cleaved to total form ratio similar to the control ( Figure 2C ). In addition, our results were confirmed by caspases 3/7, 8, and 9 activities, which were all higher in miR-28-5p-transfected cells than in the SCR-transfected cells (Supplementary Figure 6C ). In order to analyze possible differences in the cell cycle, the HCT116 cell line was transfected with either SCR, miR-28-5p, or miR-28-3p and analyzed by fluorescentactivated cell sorting. Compared with the control, cells transfected with miR-28-5p had a significantly higher percentage of cells in G1 phase and a significantly lower percentage of cells in S phase, suggesting that miR-28-5p causes G1 arrest (P Ͻ .05) ( Figure 2D ). Despite being concomitantly transcribed and being part of the same RNA stem-loop hairpin, these data suggest that miR-28-5p has a tumor-suppressive role in CRC and that miR-28-3p does not have the same biologic role.
miR-28 Disrupts Tumor Growth In Vivo
Because our in vitro studies indicated that miR-28-5p acts as a tumor suppressor in CRC, we analyzed the overall effect of miR-28 in vivo. For that purpose, we generated stable clones overexpressing miR-28, and expression of miR-28-5p and miR-28-3p was verified by quantitative real-time PCR (Supplementary Figure 7) . HCT116 colon cancer cells stably transfected with pBABE-empty or pBABE-miR-28 were subcutaneously injected into the left and right flanks of each mouse, respectively (n ϭ 9). Both cell lines were injected into the same mice to decrease inter-mouse variability. Tumors derived from the HCT116 stably expressing pBABE-miR-28 cells grew much slower than did tumors derived from the HCT116 stably expressing pBABE-empty cells ( Figure 3A) . Accordingly, final tumor volume in pBABE-miR-28 tumors was significantly reduced (P Ͻ .01) compared with pBABE-empty tumors ( Figure 3B and C). miR-28 expression levels were confirmed in these tumors. In pBABEmiR-28 tumors, miR-28-5p and miR-28-3p were increased (P Ͻ .01) when compared with pBABE-empty tumors ( Figure 3D ). In conclusion, this xenograft experiment revealed that expression of miR-28 disrupts tumor growth in vivo.
Opposite Effects of miR-28-5p and miR-28-3p in Cell Migration and Invasion
To better understand the biological importance of miR-28-5p and miR-28-3p in CRC, we explored whether these miRNAs could be involved in colon cancer metastasis. To evaluate the migratory capacity of HCT116 cells expressing either miRNA, we used Transwell cell migration assays. Overexpression of miR-28-5p led to a significant reduction in cell migration (P Ͻ .01), whereas overexpression of miR-28-3p led to a significant increase (P Ͻ .05) in cell migration compared with the control ( Figure  4 ). The same result was obtained when using SW480 transfected cells (miR-28-5p, P Ͻ 0.05; miR-28-3p; P Ͻ .01) (Supplementary Figure 8) . To determine whether both miR-28-5p and miR-28-3p also played a role in invasion, we used Transwell chambers coated with Matrigel. HCT116 cells expressing miR-28-5p had a reduction in invasiveness (P Ͻ .05), whereas cells expressing miR-28-3p had an increase in invasiveness (P Ͻ .01) compared with the control (Figure 4) . Although no statistically significant differences were obtained for SW480 cell line, the same trend was observed-miR-28-5p overexpressing cells are less invasive and miR-28-3p are more invasive than control (miR-28-5p, P ϭ .25; miR-28-3p, P ϭ .12) (Supplementary Figure 8 ). The effect of miR-28-3p, which showed a growth rate similar to the control, on migration and invasion appears to be independent of cell growth. Therefore, although both miRNAs are down-regulated in CRC, they play different roles in the migration phenotype.
mir-28 Increases Metastasis In Vivo
As miR-28-5p and miR-28-3p exert opposite effects on migration and invasion in vitro but are transcribed concomitantly in cells, we investigated the effect of global miR-28 expression on metastasis in vivo. For this purpose, we intravenously injected mice with pBABE-empty or pBABE-miR-28 cells. After 35 days, the mice were sacrificed. At necropsy, tumors were found in the liver, kidney, lung, and spinal cord. We found increased number of mice with metastases in all tumor sites in the pBABEmiR-28 group compared with the pBABE-empty group ( Figure 5A ). In particular, metastases in the liver and lung were found at a statistically significant higher frequency in the pBABE-miR-28 group than were in the pBABEempty group (P Ͻ .05). Examples of tumor metastases from the 3 most frequent locations-liver, kidney, and lung-are presented with H&E staining and anti-green fluorescent protein labeling ( Figure 5B ). In addition, the number of tumors in liver and kidney was higher in the pBABE-miR-28 group than in pBABE-empty ( Figure 5C ). In particular, in the pBABE-miR-28 group, 6 mice presented liver tumors with a mean of 1.5 Ϯ 0.8 tumors per mice, and in the pBABE-empty group, there was only 1 mouse that developed only 1 liver tumor. Regarding the kidney, in the pBABE-miR-28 group, 10 mice presented kidney tumors, with a mean of 14.6 Ϯ 4.2 tumors per mice (considering both kidneys), and in the pBABE-empty group, 6 mice developed kidney tumors, with an average of 6 Ϯ 4.2 tumors per mice (P Ͻ .005). An example of the tumors can be visualized in Figure 5D . Although miR-28-5p and miR-28-3p had contrasting effects on migration and invasion in vitro, and although in vivo subcuta-
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miR-28-5p and miR-28-3p Targets
To identify miR-28-5p and miR-28-3p targets that could be involved in the biological effects caused by these miRNAs, we first used an in silico approach. By selecting the targets predicted to be regulated by miR-28-5p or miR-28-3p in PITA, TargetScan, and miRanda programs simultaneously, we found 5784 mRNAs. Of these mRNAs, 2629 were predicted to be a target of miR-28-5p but not miR-28-3p; 1305 were predicted to be a target of miR-28-3p but not miR-28-5p; and 925 were predicted to be targets of both miRNAs. To narrow the list of potential targets, we focused on those that have been described as up-regulated in colon cancer (given that miR-28 is downregulated) and have been reported to be involved in the biological functions investigated here. Therefore, we searched for miR-28-5p targets involved in proliferation and miR-28-3p targets involved in metastasis, and we considered targets that were predicted by at least 2 programs. In this way, we identified CCND1, HOXB3, and NM23-H1.
We first used immunoblotting to detect changes at the protein level for several predicted targets of interest in cells transfected with SCR, miR-28-5p, or miR-28-3p. We 290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347   C  O  L  O  R   290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347 found a 51% reduction in the level of cyclin D1 (encoded by the CCND1 gene) in cells in which miR-28-5p was restored. On the contrary, no differences in cyclin D1 levels were detected in miR-28-3p-expressing cells compared with SCR-transfected cells ( Figure 6A ). We also found that HOXB3 was a target of miR-28-5p because this miRNA reduced HoxB3 protein expression by 35% ( Figure  6B ). Regarding miR-28-3p, we found that the protein Nm23-H1 was down-regulated by 52% in cells expressing miR-28-3p ( Figure 6C ).
To determine whether the effect on these targets was caused by direct binding of the miRNAs or by an indirect effect, we cloned the predicted mRNA binding sites (Figure 6D and E; Supplementary Figure 9 ) downstream of the modified coding region of firefly luciferase in pGL3 reporter vector. We found that miR-28-5p significantly reduced luciferase activity in the HOXB3 reporter construct by 38% (P Ͻ .01) ( Figure 6D ). Also, miR-28-3p reduced luciferase activity in the NM23-H1 reporter construct by 34% (P Ͻ .01) (Figure 6E) , and no significant differences were found when cells were cotransfected with miR-28-5p and the NM23-H1 construct (Supplementary Figure 10) . To confirm this specific interaction, we mutated the miRNA-binding sites, and the luciferase activity for the PGL3-HOXB3 and PGL3-NM23-H1 constructs was restored to the same levels as the control. Regarding CCND1, although we found a significant decrease in luciferase activity in miR-28-5p-transfected cells, the binding site mutation did not fully restore the luciferase activity to the control level (Supplementary Figure 9) . In summary, we found that miR-28-5p targeted cyclin D1 and HoxB3 and that miR-28-3p targeted Nm23-H1; this could explain, at least in part, the biological effects observed.
Discussion
In the present study, we analyzed 2 independent sets of human CRC samples, for a total of 108 (47 paired with normal tissue), and found significant down-regulation of both mature miR-28 forms. Our study is the first to show down-regulation of miR-28 in cancer. In the literature, only 1 study extensively analyzed miR-28 function in cancer, namely in myeloproliferative neoplasms. Girardot et al identified miR-28 overexpression in platelets of BCR-ABL-negative myeloproliferative neoplasm patients and found MLP to be the main target, which is important for megakaryocyte differentiation. 15 In normal colon tissue, in situ hybridization shows that miR-28-5p and miR-28-3p are predominantly expressed in epithelial cells (Supplementary Figure  11) . In addition, a couple of profiling studies showed miR-28 up-regulation in renal cell carcinoma 16 and during glioma progression. 17 It is well established that miRNAs can function as either tumor suppressors or oncogenes, depending on the tumor tissue and the cell type. 5 Therefore, when studying miRNAs, it is essential to take into consideration the cellular context. 5, 18 One of the best examples is miR125a/b, which has been shown to be down-regulated in glioblastoma, breast, prostate, ovarian, and nonϪsmall cell lung cancer, but up-regulated in myelodysplastic syndrome and acute myeloid leukemia patients with t(2;11)(p21;q23) and in urothelial carcinoma. 18, 19 Noteworthy, miRNA variation levels between normal tissue and tumors of Ͻ50% are reported frequently, and Volinia et al, who represent the largest miRNA profiling study reported so far, shows as highly significant consistent variations of Ͻ20%. 20 As down-regulation miR-28-5p and miR-28-3p had never been described before, we analyzed their roles in 348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405   F6   348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404 CRC in detail. This study provides evidence that strandspecific 5p and 3p miRNAs have distinct functions (Figure 6F) . Concordantly with the role of a tumor-suppressor gene, miR-28-5p suppressed cell proliferation, causing apoptosis and G1 arrest in the cell cycle; however, miR-28-3p had no effect on proliferation in vitro. Therefore, the overall effect in vivo was, as expected, a significant decrease in tumor volume. In contrast, miR-28-5p and miR-28-3p caused opposite effects in migration and invasion in vitro. The miR-28 -injected mice developed more metastases than did the control mice, which is in agreement with the in vitro effect observed for miR-28-3pϪoverex-pressing cells. To our knowledge, only 2 studies have addressed the distinct roles of 5p and 3p strands, but none of them have investigated the in vivo effect or the distinct targeting mechanisms in detail. These studies showed the different effects of miR-125a-3p and miR125a-5p in lung cancer cells 19 and miR-34c-3p and miR34c-5p in the cervical tumor cell line SiHa. 21 Recently, Yang et al identified the erythroid 2-related factor 2 as a target of miR-28 in breast cancer. 22 To understand the underlying mechanisms of miR-28, we searched for miRNA targets ( Figure 6F ). Cyclin D1, encoded by the CCND1 gene, is a well-known oncogene that is overexpressed in several types of tumors, including CRC. 23 This protein is a key player in cell-cycle regulation, in particular in the G1ϪS phase transition, 24, 25 and its inhibition reduces growth and tumorigenicity in human colon cancer cells. 26 We found that miR-28-5p, but not miR-28-3p, targets cyclin D1. This is in agreement with the biological functions of miR-28-5p, as only miR-28-5p and not miR-28-3p caused G1 arrest. Although cyclin D1 protein levels were decreased in miR-28-5pϪtransfected cells, it remains to be determined whether this is a consequence of a direct miR::mRNA interaction or 406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463   C  O  L  O  R   406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463 an indirect effect through miR-28-5p targeting of other mRNAs in pathways where cyclin D1 is involved. The miR-28-5p::CCND1 binding site predicted in silico showed a slight luciferase reduction that was not abrogated by the binding site mutation, showing that at least in this site there is no direct interaction. However, and although not predicted by our program's analysis, we do not exclude the possibility that other miR-28-5p::CCND1 binding sites might exist. In addition, we also found HOXB3 to be a target of miR-28-5p. HOXB3 has been described as being significantly overexpressed in colon cancer. 27 Although the role of HOXB3 in colon cancer has not been explored, Palakurthy et al described a mechanism by which HOXB3 exerts it oncogenic role, showing that it is essential for epigenetic silencing of the tumor-suppressor RASSF1A, 28 the promoter of which is hypermethylated in colon tumors. 29 These authors also demonstrate in a lung cancer cell line that HOXB3 increases tumor growth both in vitro and in vivo. 29 In addition, HOXB3 has been demonstrated to regulate cellular proliferation of hematopoietic stem cells 30 and of Rat-1 cell line. 31 The interaction between miR-28-5p and HOXB3 occurs through a direct binding as demonstrated by the luciferase assay results. Our data demonstrate that, in vivo, miR-28 promotes metastasis and that, in vitro, miR-28-3p induces migration and invasion. As miR-28 was reduced in the tumors, we looked for an antimetastatic mRNA as a target, which would suppress metastasis without affecting tumor growth. 32 Interestingly, we found that miR-28-3p has the capacity of regulating NM23-H1, the first metastasis-suppressor gene identified. [33] [34] [35] Remarkably, it has been previously The bottom panels show luciferase activity for the predicted interaction sites (D) PGL3-HOXB3-WT constructs cotransfected with scrambled negative control (n ϭ 1) or miR-28-5p and (E) PGL3-NM23-H1-WT construct cotransfected with scrambled negative control (n ϭ 1) or miR-28-3p. The same experiment was also performed using constructs with a mutated interaction site-PGL3-HOXB3-Mut and PGL3-NM23-H1-Mut.
Values represent the mean Ϯ standard deviation of 2 independent experiments performed in 4 replicates ( ** P Ͻ .01, Student t test). (F) The proposed mechanism for miR-28-5p and -3p function in CRC is shown.
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In conclusion, this is the first study to report downregulation of miR-28 in human tumorigenesis. In CRC, miR-28 suppresses proliferation but activates metastasis; this is a consequence of the distinct roles of the miR-28 hairpin RNA products, miR-28-5p and miR-28-3p. Such information has direct consequences for the design of miRNA gene therapy trials. The manipulation of the expression of specific miRNAs by using the precursor molecules can produce additional clinical effects due to the transcription of 5p and 3p genes with distinct biological effects.
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Supplementary Methods
Microsatellite Analysis
Microsatellite analysis was performed on DNA extracted from frozen tissue samples by a standard phenol-chloroform procedure. MSI was evaluated with a fluorescence-based PCR method using the 5 markers of the Bethesda panel (ie, D5S346, D17S250, D2S123, BAT25, and BAT26) plus BAT40. Analysis of PCR products was done with an automated DNA sequencer. Tumors were classified as MSS, MSI-L, and MSI-H according to the guidelines of the International Workshop of Bethesda. 1
RNA and Protein Extraction
RNA was isolated using Trizol reagent (Invitrogen), according to manufacturer's instructions. RNA quantity and purity was assessed with NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE). RNA integrity was analyzed by gel electrophoresis. RNA samples were denaturated at 70°C for 5 minutes, immediately placed on ice, and loaded on an agarose gel stained with ethidium bromide. Intensity of the 18S and 28S bands was examined.
Total protein extracts were prepared in ice-cold lysis buffer (0.5% Nonidet P-40, 250 mM sodium chloride, 50 mM HEPES, 5 mM EDTA, and 0.5 mM ethylene glycolbis(␤-aminoethyl ether)-N,N,N=,N=-tetraacetic acid) containing phosphatase inhibitor cocktail 2 (Sigma-Aldrich, St Louis, MO), protease inhibitor (Clontech, Mountain View, CA), and dithiothreitol (Invitrogen).
Reverse Transcription Quantitative RealTime PCR
miRNA expression was evaluated using TaqMan miRNA assays (Applied Biosystems). Briefly, complementary DNA was synthesized using RNA as a template, genespecific stem-loop Reverse Transcription primer, and the TaqMan microRNA reverse-transcription kit (Applied Biosystems). Quantitative real-time PCR was carried out in a CFX384 real-time system (Bio-Rad, Hercules, CA) using complementary DNA, TaqMan probe, and TaqMan universal PCR master mix (Applied Biosystems). Experiments were performed in duplicate and normalized to small nuclear RNA U6, which was used as an internal control. Relative expression levels were calculated using the comparative cycle threshold method. Stability of the reference gene between samples was analyzed. PCR efficiency was determined using the formula: Efficiency ϭ 10 Ϫ1/slope Ϫ1.
Cell Culture, STR DNA Fingerprinting, and miRNA Mimics Transfection
Human CRC HCT116, RKO, and SW480 cell lines (purchased from American Type Culture Collection, Manassas, VA) were grown as suggested by the supplier. Cells were cultured at 37°C in 5% CO 2.
All cell lines used in this study were validated by STR DNA fingerprinting using the AmpFᐉSTR Identifiler kit, according to manufacturer instructions (Applied Biosystems). The STR profiles were compared with known ATCC fingerprints (ATCC.org), to the Cell Line Integrated Molecular Authentication database version 0.1.200808 (http:// bioinformatics.istge.it/clima/), 2 and to the MD Anderson fingerprint database. STR profiles of HCT116, RKO, and SW480 cell lines matched known DNA fingerprints and were unique.
Pre-miRNA miRNA precursor molecules for hsa-miR-28-5p and hsa-miR-28-3p and pre-miR miRNA precursor scrambled negative control (SCR) #2 were purchased from Ambion (Austin, TX). Transfections were performed using 50 nM miRNA specific-strand precursor molecules or control and Lipofectamine 2000 reagent (Invitrogen), according to manufacturer's instructions. RNA and proteins were collected at 48 hours after transfection. miRNA transfection efficiencies were evaluated by reverse transcription quantitative real-time PCR.
3-(4,5-Dmethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) Assay
We seeded 5 ϫ 10 3 HCT116 cells transfected with either SCR or miR-28-5p in a 96-well plate in 8 replicates for each condition. At each time point (0, 24, 48, 72, and 96 hours post transfection), the colorimetric reagent was added to the cells. After 2-hour incubation at 37°C, dimethylsulfoxide was added. Proliferation was assessed by measuring absorbance at 580 nm using the SpectraMax Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA). Experiment was performed 2 times independently.
Apoptosis Quantification
Protein levels of the apoptotic molecular marker PARP1, full-length, and cleavage PARP1 forms were assessed by Western blot analysis using PARP antibody (9542) from Cell Signaling Technology (Danvers, MA) in the HCT116 and RKO cell lines transfected with SCR, miR-28-5p, or miR-28-3p. Relative intensity of bands observed by Western blotting was obtained using ImageJ software (http://imagej.nih.gov/ij/). In addition, caspase 3/7, 8, and 9 activity was measured.
Caspase 3/7, 8, and 9 Activity
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Cell-Cycle Analysis by Flow Cytometry
For fluorescent-activated cell sorting analysis, 6 ϫ 10 5 HCT116 cells transfected with either SCR, miR-28-5p, or miR-28-3p were plated onto 6-well plates. After 48 hours, cells were collected and fixed with 70% ice-cold ethanol. Cells were stained with a solution containing 0.05 mg/mL propidium iodide (Sigma-Aldrich) and 0.1 mg/mL RNase A (Roche, Indianapolis, IN) in phosphate-buffered saline. Cell-cycle analysis was performed in a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). Results were analyzed using ModFit LT software.
In Vitro Cell Migration and Invasion Assays
After 24-or 48-hour incubation (for migration and invasion assay, respectively) at 37°C with 5% CO 2 , cells were fixed with paraformaldehyde (USB Corporation, Cleveland, OH). Cells on the upper surface of the chamber (nonmigratory cells) were removed using cotton swabs, and cells on the bottom surface (migratory cells) were stained with crystal violet in 20% methanol for 20 minutes. Finally, 30% acetic acid was added to dissolve the crystal violet and absorbance was measured in a SpectraMax Plus 384 spectrophotometer (Molecular Devices) at 590 nm.
Establishment of miR-28-Expressing Cell Line: Cell Transduction With Retroviral Vector
A PCR fragment of 483 nt that included the human miR-28 precursor and flanking sequences was amplified using primers with BamHI and EcoRI endonucleases restriction sites (Supplementary Table 4 ). pBABE-puro retroviral plasmid and miR-28-containing fragment were digested with BamHI and EcoRI enzymes and ligated using T4 DNA ligase (New England Biolabs, Ipswich, MA). Constructs were checked by direct sequencing. The retroviral plasmid pBABEmiR28 was transiently transfected together with pVSV-G vector into GP2-293 cells using Lipofectamine 2000 reagent (Invitrogen). The retroviral plasmid pBABE-empty was used as a control. Cells were fed with fresh medium the day after transfection. Viral supernatant was collected 3 days after transfection, filtered through 0.45-m pore, and supplemented with Sequa-brene (Sigma-Aldrich). HCT116 cells, which are known to have metastatic potential, 3 were infected and selected using puromycin. Successful establishment of HCT116-pBABE-miR28 cell line was verified by reverse transcription quantitative real-time PCR.
Cell Transduction With Lentiviral Vector
As pBABE-puro does not contain green fluorescent protein marker, and to facilitate the detection of the human colon cancer cells in the in vivo studies, HCT116-pBABE-empty and HCT116-pBABE-miR28 cells were transduced in parallel with empty pRRL-CMV-PGK-GFP-WPRE (Tween) lentiviral vector. Briefly, pTween vector was cotransfected with the packaging vector pCM-VDR8.74 and the envelope vector pMD.G into 293FT cells using Lipofectamine 2000 reagent. Forty-eight hours after transfection, supernatant containing the virus was collected, filtered through 0.45-m pore, and supplemented with Sequa-brene. HCT116-pBABE-empty and HCT116-pBABE-miR28 were incubated with the viral soup for 45 minutes and centrifuged at 32°C at 1800 rpm, plus another 1 hour and 15 minutes in the incubator at 37°C. Infection efficiency was evaluated by flow cytometry by detecting the percentage of green fluorescent protein-positive cells (Ͼ85%).
miRNA Target Prediction
We performed in silico analysis to determine miR-28-5p-and miR-28-3p-predicted targets using an in-house Perl script that scans the databases for the algorithms PITA (http://genie.weizmann.ac.il/pubs/mir07), TargetScan (http:// www.targetscan.org), miRanda (http://www.microrna.org), and RNA22 (http://cbcsrv.watson.ibm.com/) for target identification. miR-28 sequence annotation was obtained from the miRBase database (http://www.mirbase.org/) (Supplementary Table 4 ).
Western Blot Analysis for miRNA Targets
Proteins were collected 48 hours after cells were transfected with SCR, miR-28-5p, or miR-28-3p. Bradford assay was used to measure protein concentration. Proteins were separated by polyacrylamide gel (Bio-Rad) electrophoresis and were transferred to 0.2-m nitrocellulose membranes (Bio-Rad). The following antibodies were used: anti-cyclin D1 (sc-20044), anti-HoxB3 (sc-28606), and anti-Nm23-H1 (sc-343) all from Santa Cruz Biotechnology (Santa Cruz, CA). Proteins were detected by chemiluminescence. AntiϪglyceraldehyde-3-phosphate dehydrogenase from Cell Signaling Technology or anti-vinculin (sc-5573) from Santa Cruz Biotechnology were used as normalizers.
Luciferase Reporter Assays
Fragments of about 200 nt that contained the miR-28-5p and miR-28-3p putative binding sites were amplified by PCR using primers containing the XbaI restriction enzyme site (Supplementary Table 4 ). PCR products were purified, digested, and directly cloned into the Xbal site of the pGL3 control vector (Promega Corporation, Madison, WI) located downstream of the firefly luciferase reporter gene. The QuikChange II XL sitedirected mutagenesis kit (Agilent Technologies, Santa Clara, CA) was used to generate mutations in the miRNA-binding site (Supplementary Table 4 806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861   806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859 860 861
Supplementary Figure 3 . Twenty-four normal specimens from the first set of patients were paired with colon cancer tissues from the same patient. All values of miRNA expression levels were normalized by small nuclear RNA U6. Significant differences were ***P Ͻ .005 using paired t test.
Supplementary Figure 4.
Endogenous levels of miR-28-5p and miR-28-3p in 10 colon cancer cell lines. Small nuclear RNA U6 was used as a normalizer.
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Supplementary Figure 11 . In situ hybridization analysis for miR-28-5p and miR-28-3p in normal colon tissue. Frozen tissue sections were digested with proteinase K and loaded onto Ventan Discovery Ultra. The tissue slides were incubated with double-DIG labeled miRCURY LNA Detection probe and the digoxigenin was detected with a polyclonal anti-DIG antibody and UltraMap Blue anti-Ms Detection Kit. H&E staining was performed. Microscopy images were obtained with a magnification of 100ϫ.
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